MONROVIA, Calif.—STAAR Surgical Company announced that the FDA has granted approval of the PMA Supplement for the Visian Toric ICL for the correction of myopia with astigmatism. “FDA’s approval of STAAR’s Visian Toric ICL in the U.S. provides an exciting treatment option for myopic patients with astigmatism in search of visual freedom. We are thrilled to be able to offer this lens in the U.S. and look forward to officially making the Visian Toric ICL available to U.S. surgeons for their patients on Nov. 1, 2018,” said Caren Mason, president and CEO.

Astigmatism affects approximately 30 percent of the population, the company noted. The approval of the Visian Toric ICL is also an important step toward the future availability of advanced ICL models in the U.S., such as the EVO/EVO+ Toric ICL, STAAR said in a statement.